

## SDC, Materials and Methods

---

### **Search Strategy**

#### **Medline**

1. exp kidney transplantation/
2. exp Nephrectomy/
3. renal transplant\$.ti,ab.
4. 1 or 2 or 3
5. exp guideline/
6. (guideline or practice guideline).pt.
7. guideline.ti,ab.
8. exp consensus/
9. consensus.tw.
10. position statement\$.tw.
11. exp policy/
12. 5 or 6 or 7 or 8 or 9 or 10 or 11
13. 4 and 12
14. limit 13 to (english language and yr="2010 -Current")

#### **Embase**

1. exp kidney transplantation/
2. exp nephrectomy/
3. renal transplant\$.ti,ab.
4. 1 or 2 or 3
5. exp practice guideline/
6. guideline\$.tw.
7. guideline.ti,ab.
8. consensus.tw.
9. position statement\$.tw.
10. exp health care policy/ or exp policy/
11. 5 or 6 or 7 or 8 or 9 or 10

12. 4 and 11

13. limit 12 to (english language and yr="2010 -Current")

14. limit 13 to (conference abstract or conference proceeding)

15. 13 not 14

### **NHS/NICE Evidence Search**

"kidney transplant\*" or "renal transplant\*" or nephrectomy

### **The National Guideline Clearinghouse**

"kidney transplant\*" or "renal transplant\*" or nephrectomy

---

### **List of Included Societies**

ABTO - Brazilian Association of Organ Transplantation

ASN - American Society of Nephrology

AST - American Society of Transplantation

ASTS - American Society of Transplant Surgeons

AOTO - Association of Organ Procurement Organizations

British Renal Society

BTS - British Transplantation Society

CST - Canadian Society of Transplantation

EAU - European Association of Urology

ERA-EDTA [ERBP] - European Renal Association-European Dialysis and  
Transplantation Association

ESOT - European Society of Organ Transplantation

ESPN - European Society for Paediatric Nephrology

IPTA - International Society for Paediatric Transplantation

KDIGO - Kidney Disease: Improving Global Outcomes

KHA CARI - Kidney Health Australia – Caring for Australasians with Renal  
Impairment

NHSBT - NHS Blood and Transplant

NICE - National Institute for Health and Care Excellence

TSANZ - The Transplantation Society of Australia and New Zealand

TTS - The Transplantation Society

The Renal Association

---

## **AGREE II Domains and Items**

<b>AGREE II Domain</b>	<b>AGREE II Item</b>
Scope and Purpose	1. The overall objective(s) of the guideline is (are) specifically described. 2. The health question(s) covered by the guideline is (are) specifically described. 3. The population (patients, public, etc.) to whom the guideline is meant to apply is specifically described.
Stakeholder Involvement	4. The guideline development group includes individuals from all the relevant professional groups. 5. The views and preferences of the target population (patients, public, etc.) have been sought. 6. The target users of the guideline are clearly defined.
Rigour of Development	7. Systematic methods were used to search for evidence. 8. The criteria for selecting the evidence are clearly described. 9. The strengths and limitations of the body of evidence are clearly described. 10. The methods for formulating the recommendations are clearly described. 11. The health benefits, side effects, and risks have been considered in formulating the recommendations. 12. There is an explicit link between the recommendations and the supporting evidence. 13. The guideline has been externally reviewed by experts prior to its publication. 14. A procedure for updating the guideline is provided.
Clarity of Presentation	15. The recommendations are specific and unambiguous. 16. The different options for management of the condition or health issue are clearly presented. 17. Key recommendations are easily identifiable.
Applicability	18. The guideline describes facilitators and barriers to its application. 19. The guideline provides advice and/or tools on how the recommendations can be put into practice. 20. The potential resource implications of applying the recommendations have been considered. 21. The guideline presents monitoring and/ or auditing criteria.
Editorial Independence	22. The views of the funding body have not influenced the content of the guideline. 23. Competing interests of guideline development group members have been recorded and addressed